The single-arm phase II study evaluating pomalidomide-plus-dexamethasone for relapsed/refractory multiple myeloma and phase II study evaluating pomalidomide-bortezomib-dexamethasone for the patients who are not able to achieve PR after pomalidomide-plus-dexamethasone therapy
Latest Information Update: 10 Oct 2022
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms J-MEN 010 Study
- 09 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.
- 03 Aug 2017 New trial record